The Korean Pharmaceutical Association expressed strong concerns about the ‘non-face-to-face treatment’ pilot project that will be implemented from the 1st of next month.
The Pharmaceutical Society pointed out today (30th), “If faceless treatment is allowed quickly as it is now, the harm caused by misdiagnosis, excessive treatment, and the misuse of medicines will focus on the class exposed to medically impaired, such as those with mobility difficulties.”
He continued, “The non-face-to-face treatment pilot project appears to have been rushed through something without adequate review or evaluation.”
In particular, the Pharmaceutical Society argued that “a regulatory mechanism for intermediary platform companies is not sufficiently prepared” and that “abnormal handling and illegal distribution of medicines could be rampant.”
At the same time, ″For patients with diseases other than chronic diseases, unlimited non-face-to-face treatment is allowed for return visits within 30 days, and there are no restrictions on prescriptions for non-essential medicines and can be reimbursed such as hair loss and acne, or practical sanctions against illegal actions by platform companies.″ was identified as an urgent problem.
The pharmacists’ association also disputed the fact that fax or e-mail prescriptions were allowed in the pilot project, that identification procedures were not specifically introduced when receiving drugs by proxy or at home, and that the end date of the pilot project was not specified . are problems too.
However, the pharmacists’ association assessed that it was “fortunate out of misfortune” that the scope of home collection of medicines was minimized.
